论文部分内容阅读
生物制药公司Stemline Therapeutics宣布,美国FDA已授予其临床新药SL-401突破性疗法认定。该新型药物可靶向白介素-3受体(CD123),用于治疗急浆细胞样树突状细胞肿瘤(BPDCN)。
Stemline Therapeutics, a biopharmaceutical company, announced that the U.S. FDA has awarded breakthrough approval for its clinical drug SL-401. The new drug targets interleukin-3 receptor (CD123) for the treatment of acute plasmacytoid dendritic cell tumor (BPDCN).